Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells

Rajavithi Hospital

Status: Completed

Conditions: Metformin; CA Endometrium

Treatments: Drug: Metformin Hydrochloride 850 MG; Drug: Placebo Oral Tablet

Study type: Interventional

Funder types: Other

Identifiers

NCT03618472

Rjmetformin

Details and patient eligibility

About

Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in endometrial cancer cells.

Full description

Endometrial cancer is one of the most common gynecological cancers. Preclinical studies in endometrial cancer (EC) show that metformin reduces cellular proliferation by PI3K-AKT-mTOR inhibition. The investigators tested the hypothesis that short-term presurgical metformin reduces cellular proliferation in endometrial cancer. However, no good quality of evidence base supports the effectiveness of metformin for deceasing proliferative marker in endometrial cancer.

Enrollment: 50 patients

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Women with endometrial cancer who undergoing complete surgical staging and agrees to participate in this study

Exclusion criteria

• Women without diabetes type 1 and 2
• Women who have allergy Biguanide
• Women who have hypoglycemic medication
• Women who have GFR <45 ml/min/1.73 m2
• Women who have evidence of stage 3 or 4 of endometrial cancer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups, including a placebo group

metformin

Experimental group

Description:

The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy

Treatment:

Drug: Metformin Hydrochloride 850 MG

placebo

Placebo Comparator group

Description:

The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy

Treatment:

Drug: Placebo Oral Tablet